Published in J Natl Cancer Inst on April 05, 2000
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Methylation matters. J Med Genet (2001) 3.00
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
Age-associated DNA methylation in pediatric populations. Genome Res (2012) 2.53
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 2.36
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
Epigenetics and human disease: translating basic biology into clinical applications. CMAJ (2006) 1.98
The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 1.80
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res (2006) 1.80
Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer (2009) 1.78
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A (2006) 1.70
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med (2008) 1.70
Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis (2003) 1.69
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med (2011) 1.68
MYC and Breast Cancer. Genes Cancer (2010) 1.66
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol (2010) 1.60
Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia (2010) 1.58
DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol (2013) 1.57
Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol (2001) 1.53
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol (2005) 1.52
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer (2007) 1.44
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol (2009) 1.43
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol (2015) 1.41
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res (2009) 1.37
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer (2006) 1.34
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res (2008) 1.30
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
DNA methylation: an alternative pathway to cancer. Ann Surg (2001) 1.24
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle (2013) 1.23
DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis (2012) 1.22
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat (2007) 1.22
Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer (2001) 1.21
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A (2010) 1.20
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res (2014) 1.18
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One (2009) 1.18
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics (2011) 1.17
Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer (2002) 1.13
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol (2014) 1.12
Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics (2013) 1.11
Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol (2011) 1.11
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. Mol Cell Biol (2003) 1.10
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat (2008) 1.10
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer (2006) 1.08
DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol (2009) 1.08
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
Epigenetics of gestational diabetes mellitus and offspring health: the time for action is in early stages of life. Mol Hum Reprod (2013) 1.07
Treatment options for patients with triple-negative breast cancer. J Hematol Oncol (2010) 1.07
Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer (2009) 1.07
Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle (2013) 1.07
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 1.05
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res (2014) 1.05
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics (2012) 1.05
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. BMC Cancer (2013) 1.04
BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol (2014) 1.03
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci (2013) 1.02
Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev (2012) 1.01
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle (2012) 1.00
Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol (2009) 1.00
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol (2005) 1.00
BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Cell Death Dis (2012) 0.99
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev (2009) 0.99
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res (2014) 0.99
Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med (2009) 0.98
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J (2010) 0.98
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther (2013) 0.97
Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res (2007) 0.96
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer (2001) 0.96
Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res (2012) 0.96
A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1. PLoS One (2012) 0.96
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist (2013) 0.95
Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat (2009) 0.95
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res (2009) 0.95
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One (2013) 0.95
Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) (2016) 0.95
Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer. Epigenetics (2012) 0.95
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol (1996) 5.05
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol (2001) 3.80
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem (2001) 3.23
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (2000) 2.94
Widespread occurrence of avian spectrin in nonerythroid cells. Cell (1982) 2.90
Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Gate-tuning of graphene plasmons revealed by infrared nano-imaging. Nature (2012) 2.75
Expression of Snail protein in tumor-stroma interface. Oncogene (2006) 2.68
Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am (2006) 2.68
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer (1997) 2.60
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood (1999) 2.57
Inflammatory pseudotumor-like follicular dendritic cell tumor: a distinctive low-grade malignant intra-abdominal neoplasm with consistent Epstein-Barr virus association. Am J Surg Pathol (2001) 2.55
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Methylation-specific PCR simplifies imprinting analysis. Nat Genet (1997) 2.33
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol (1996) 2.26
DNA methylation, chromatin inheritance, and cancer. Oncogene (2001) 2.26
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A (1988) 2.14
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res (1997) 2.12
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A (1991) 2.07